SCHEMBL24993307

SCHEMBL24993307

CCc1cncc(C(=O)NN)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 5/20 0.42
KDM4E B2RXH2 3/20 0.42
MRGPRX4 Q96LA9 1/20 0.38
GAA P10253 2/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
MPO P05164 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2A6 P11509 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MCL1 Q07820 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PDE5A O76074 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7573577 0.81 ADORA3 (0.42) KDM4EMRGPRX4ADORA3
SCHEMBL24609419 0.81 CNR2 (0.38) MRGPRX4ALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL15272578 0.79 MRGPRX4 (0.38) MRGPRX4MAPTALDH1A1PDE5ANPC1
SCHEMBL1760358 0.79 HCAR2 (0.41) KDM4EMRGPRX4MAPTALDH1A1CYP1A2
SCHEMBL14872363 0.79 MRGPRX4 (0.57) MRGPRX4ALDH1A1NPC1RAB9APDE4A
SCHEMBL22518525 0.78 P2RX7 (0.58) P2RX7KDM4EGAAMAPTALDH1A1
SCHEMBL18245756 0.75 P2RX7 (0.64) P2RX7KDM4EGAAMAPTALDH1A1
SCHEMBL28139894 0.74 KDM4E (0.49) P2RX7KDM4EGAAMAPTALDH1A1
SCHEMBL13771995 0.74 BAZ2B (0.42) KDM4EMRGPRX4CYP1A2CYP3A4
SCHEMBL24993310 0.74 P2RX7 (0.41) P2RX7KDM4EGAAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 US disclosed
WO-2023010191-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS SCN1A, SCN7A, SCN8A P2RX7 160/4885KDM4E 2030/4885MRGPRX4 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.